VHL Disease

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 24, Issue 3, 2010, Pages 401-413

  Barontini, Marta ^a   Dahia, Patricia L M ^b  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

angiogenesis; haemangioblastoma; hereditary tumour; HIF; hypoxia; paraganglioma; phaeochromocytoma; renal carcinoma; VHL; von Hippel Lindau disease

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; REACTIVE OXYGEN METABOLITE; SORAFENIB; SUNITINIB; UVOMORULIN; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; CLINICAL FEATURE; ENDOLYMPHATIC SAC TUMOR; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENOTYPE PHENOTYPE CORRELATION; HEMANGIOBLASTOMA; KIDNEY CANCER; KIDNEY CARCINOMA; NONHUMAN; PANCREAS CYST; PANCREAS TUMOR; PEDIATRICS; PHEOCHROMOCYTOMA; PLEIOTROPY; RETINA HEMANGIOMA; RETINA TUMOR; REVIEW; SENESCENCE; VESTIBULAR DISORDER; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; CARCINOMA, RENAL CELL; CHILD; CHILD, PRESCHOOL; FEMALE; HEMANGIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MALE; PHEOCHROMOCYTOMA; TOR SERINE-THREONINE KINASES; VON HIPPEL-LINDAU DISEASE; YOUNG ADULT;

EID: 77956596804     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2010.01.002     Document Type: Review

References (90)

1. E.R. Maher, and W.G. Kaelin Jr. von Hippel-Lindau disease Medicine (Baltimore) 76 6 1997 381 391
2. F. Latif, K. Tory, J. Gnarra, M. Yao, F.-M. Duh, and M.-L. Orcutt Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 1993 1317 1320 (Pubitemid 23231974)
3. B. Zbar Von Hippel-Lindau disease and sporadic renal cell carcinoma Cancer Surveys 25 1995 219 232
4. W.G. Kaelin Von Hippel-Lindau disease Annual Review of Pathology 2 2007 145 173
5. W.G. Kaelin Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer Clinical Cancer Research 10 18 Pt 2 2004 Sep 15 6290S 6295S
6. S.O. Ang, H. Chen, K. Hirota, V.R. Gordeuk, J. Jelinek, and Y. Guan Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia Nature Genetics. 32 4 2002 Dec 614 621
7. R.R. Lonser, G.M. Glenn, M. Walther, E.Y. Chew, S.K. Libutti, and W.M. Linehan von Hippel-Lindau disease Lancet 361 9374 2003 Jun 14 2059 2067
8. S.C. Clifford, M.E. Cockman, A.C. Smallwood, D.R. Mole, E.R. Woodward, and P.H. Maxwell Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel- Lindau disease Human Molecular Genetics. 10 10 2001 1029 1038
9. M.A. Hoffman, M. Ohh, H. Yang, J.M. Klco, M. Ivan, and W.G. Kaelin Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF Human Molecular Genetics. 10 10 2001 1019 1027
10. W.G. Kaelin Jr. Molecular basis of the VHL hereditary cancer syndrome Nature Reviews. Cancer 2 9 2002 Sep 673 682
11. S. Glasker, B.U. Bender, T.W. Apel, E. Natt, V. van Velthoven, and R. Scheremet The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system Journal of Neurology, Neurosurgery, and Psychiatry 67 6 1999 Dec 758 762
12. H.P. Neumann, H.R. Eggert, K. Weigel, H. Friedburg, O.D. Wiestler, and P. Schollmeyer Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome Journal of Neurosurgery 70 1 1989 Jan 24 30
13. J.E. Wanebo, R.R. Lonser, G.M. Glenn, and E.H. Oldfield The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease Journal of Neurosurgery 98 1 2003 Jan 82 94
14. I.R. Maddock, A. Moran, E.R. Maher, M.D. Teare, A. Norman, and S.J. Payne A genetic register for von Hippel-Lindau disease Journal of Medical Genetics 33 2 1996 Feb 120 127
15. A.R. Webster, E.R. Maher, A.C. Bird, Z.J. Gregor, and A.T. Moore A clinical and molecular genetic analysis of solitary ocular angioma Ophthalmology 106 3 1999 Mar 623 629
16. A.D. Singh, M. Nouri, C.L. Shields, J.A. Shields, and A.F. Smith Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease Ophthalmology 108 10 2001 Oct 1907 1911
17. A.D. Singh, M. Nouri, C.L. Shields, J.A. Shields, and N. Perez Treatment of retinal capillary hemangioma Ophthalmology 109 10 2002 Oct 1799 1806
18. C.M. McCabe, H.W. Flynn Jr., C.L. Shields, J.A. Shields, C.D. Regillo, and H.R. McDonald Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes Ophthalmology 107 12 2000 Dec 2240 2248
19. W.T. Wong, and E.Y. Chew Ocular von Hippel-Lindau disease: clinical update and emerging treatments Current Opinion in Ophthalmology 19 3 2008 May 213 217
20. K.R. Ong, E.R. Woodward, P. Killick, C. Lim, F. Macdonald, and E.R. Maher Genotype-phenotype correlations in von Hippel-Lindau disease Human Mutation 28 2 2007 Feb 143 149
21. J.J. Patard, O. Shvarts, J.S. Lam, A.J. Pantuck, H.L. Kim, and V. Ficarra Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience The Journal of Urology 171 6 Pt 1 2004 Jun 2181 2185 quiz 435
22. T.K. Choueiri, R.M. Bukowski, and B.I. Rini The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma Seminars in Oncology 33 5 2006 Oct 596 606
23. G. Bratslavsky, J.J. Liu, A.D. Johnson, S. Sudarshan, P.L. Choyke, and W.M. Linehan Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes The Journal of Urology 179 1 2008 Jan 67 70
24. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, and S.L. Topalian A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer The New England Journal of Medicine 349 5 2003 Jul 31 427 434
25. B. Mukhopadhyay, A. Sahdev, J.P. Monson, G.M. Besser, R.H. Reznek, and S.L. Chew Pancreatic lesions in von Hippel-Lindau disease Clinical Endocrinology 57 5 2002 Nov 603 608
26. J.A. Blansfield, L. Choyke, S.Y. Morita, P.L. Choyke, J.F. Pingpank, and H.R. Alexander Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs) Surgery 142 6 2007 Dec 814 818 discussion 8 e1-2
27. R. Chetty, M. Kennedy, S. Ezzat, and S.L. Asa Pancreatic endocrine pathology in von Hippel-Lindau disease: an expanding spectrum of lesions Endocrine Pathology 15 2 2004 Summer 141 148
28. P.R. Hammel, V. Vilgrain, B. Terris, A. Penfornis, A. Sauvanet, and J.M. Correas Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau Gastroenterology 119 4 2000 Oct 1087 1095
29. R.R. Lonser, H.J. Kim, J.A. Butman, A.O. Vortmeyer, D.I. Choo, and E.H. Oldfield Tumors of the endolymphatic sac in von Hippel-Lindau disease The New England Journal of Medicine 350 24 2004 Jun 10 2481 2486
30. J.A. Butman, H.J. Kim, M. Baggenstos, J.M. Ammerman, J. Dambrosia, and A. Patsalides Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease Journal of the American Medical Association 298 1 2007 Jul 4 41 48
31. E.R. Maher, and C. Eng The pressure rises: update on the genetics of phaeochromocytoma Human Molecular Genetics. 11 20 2002 Oct 1 2347 2354
32. H.P. Neumann, B. Bausch, S.R. McWhinney, B.U. Bender, O. Gimm, and G. Franke Germ-line mutations in nonsyndromic pheochromocytoma The New England Journal of Medicine 346 19 2002 May 9 1459 1466
33. B. Bausch, C.C. Boedeker, A. Berlis, I. Brink, M. Cybulla, and M.K. Walz Genetic and clinical investigation of pheochromocytoma: a 22-year experience, from Freiburg, Germany to international effort Annals of the New York Academy of Sciences 1073 2006 Aug 122 137
34. V.S. Reddy, J.A. O'Neill Jr., G.W. Holcomb 3rd, W.W. Neblett 3rd, J.B. Pietsch, and W.M. Morgan 3rd Twenty-five-year surgical experience with pheochromocytoma in children The American Surgeon 66 12 2000 Dec 1085 1091 discussion 92
35. M. Barontini, G. Levin, and G. Sanso Characteristics of pheochromocytoma in a 4- to 20-year-old population Annals of the New York Academy of Sciences 1073 2006 Aug 30 37
36. J. Gaal, F.H. van Nederveen, Z. Erlic, E. Korpershoek, R. Oldenburg, and C.C. Boedeker Parasympathetic Paragangliomas Are Part of the Von Hippel-Lindau Syndrome The Journal of Clinical Endocrinology and Metabolism 94 11 November 1, 2009 4367 4371
37. G. Eisenhofer, M.M. Walther, T.T. Huynh, S.T. Li, S.R. Bornstein, and A. Vortmeyer Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes The Journal of Clinical Endocrinology and Metabolism 86 5 2001 1999 2008
38. B. Havekes, K. King, E.W. Lai, J.A. Romijn, E.P. Corssmit, and K. Pacak New imaging approaches to phaeochromocytomas and paragangliomas Clinical Endocrinology 2009 Jun 8
39. S. Al-Sobhi, R. Peschel, C. Zihak, G. Bartsch, H. Neumann, and G. Janetschek Laparoscopic partial adrenalectomy for recurrent pheochromocytoma after open partial adrenalectomy in von Hippel-Lindau disease Journal of Endourology 16 3 2002 Apr 171 174
40. F.J. Hes, R.B. van der Luijt, A.L. Janssen, R.A. Zewald, G.J. de Jong, and J.W. Lenders Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification Clinical Genetics 72 2 2007 Aug 122 129
41. L. Santarpia, N.J. Sarlis, M. Santarpia, S.I. Sherman, F. Trimarchi, and S. Benvenga Mosaicism in von Hippel-Lindau disease: an event important to recognize Journal of Cellular and Molecular Medicine 11 6 2007 Nov-Dec 1408 1415
42. S.H. Ein, B. Shandling, D. Wesson, and R. Filler Recurrent pheochromocytomas in children Journal of Pediatric Surgery 25 10 1990 Oct 1063 1065
43. A. Hering, M. Guratowska, P. Bucsky, U. Claussen, J. Decker, and G. Ernst Characteristic genomic imbalances in pediatric pheochromocytoma Genes Chromosomes Cancer 45 6 2006 Jun 602 607
44. T. Shuin, I. Yamasaki, K. Tamura, H. Okuda, M. Furihata, and S. Ashida Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment Japanese Journal of Clinical Oncology 36 6 2006 Jun 337 343
45. F. Assadi, and E.L. Brackbill Bilateral pheochromocytomas and congenital anomalies associated with a de novo germline mutation in the von Hippel-Lindau gene American Journal of Kidney Diseases 41 1 2003 Jan E3
46. P. Reichardt, T.W. Apel, M. Domula, R.B. Trobs, I. Krause, and U. Bierbach Recurrent polytopic chromaffin paragangliomas in a 9-year-old boy resulting from a novel germline mutation in the von Hippel-Lindau gene Journal of Pediatric Hematology/Oncology 24 2 2002 Feb 145 148
47. J. Ferragut, M. Caimari, B. Rituerto, B. Gomez-Rivas, M. Herrera, and F. Alonso Pheochromocytoma and clear-cell renal carcinoma in a child with von Hippel-Lindau disease: a patient report Journal of Pediatric Endocrinology & Metabolism 12 4 1999 Jul-Aug 579 582
48. M. Priesemann, K.M. Davies, L.A. Perry, W.M. Drake, S.L. Chew, and J.P. Monson Benefits of screening in von Hippel-Lindau disease-comparison of morbidity associated with initial tumours in affected parents and children Hormone Research. 66 1 2006 1 5
49. J.M. Langrehr, M. Bahra, G. Kristiansen, H.P. Neumann, L.M. Neumann, and U. Plockinger Neuroendocrine tumor of the pancreas and bilateral adrenal pheochromocytomas. A rare manifestation of von Hippel-Lindau disease in childhood Journal of Pediatric Surgery 42 7 2007 Jul 1291 1294
50. M.M. Walther, H.R. Keiser, and W.M. Linehan Pheochromocytoma: evaluation, diagnosis, and treatment World Journal of Urology 17 1 1999 Feb 35 39
51. G. Sanso, M.C. Rudaz, G. Levin, and M. Barontini Familial isolated pheochromocytoma presenting a new mutation in the von Hippel-Lindau gene American Journal of Hypertension 17 12 Pt 1 2004 Dec 1107 1111
52. L.B. Johnston, S.L. Chew, D. Lowe, R. Reznek, J.P. Monson, and M.O. Savage Investigating familial endocrine neoplasia syndromes in children Hormone Research. 55 Suppl. 1 2001 31 35
53. J. Gaal, and R.R. De Krijger Neuroendocrine tumors and tumor syndromes in childhood Pediatric and Developmental Pathology 2009 Aug 26 1
54. W.G. Kaelin Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing Journal of the American Society of Nephrology 14 11 2003 Nov 2703 2711
55. W.G. Kaelin, O. Iliopoulos, K.M. Lonergan, and M. Ohh Functions of the von Hippel-Lindau tumour suppressor protein Journal of Internal Medicine 243 6 1998 535 539
56. M. Ivan, K. Kondo, H. Yang, W. Kim, J. Valiando, and M. Ohh HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing Science 292 5516 2001 Apr 20 464 468
57. A.C. Epstein, J.M. Gleadle, L.A. McNeill, K.S. Hewitson, J. O'Rourke, and D.R. Mole C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell. 107 1 2001 Oct 5 43 54
58. P.H. Maxwell, and P.J. Ratcliffe Oxygen sensors and angiogenesis Seminars in Cell & Developmental Biology. 13 1 2002 Feb 29 37
59. J.D. Gordan, P. Lal, V.R. Dondeti, R. Letrero, K.N. Parekh, and C.E. Oquendo HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma Cancer Cell. 14 6 2008 Dec 9 435 446
60. P.L. Dahia, K.N. Ross, M.E. Wright, C.Y. Hayashida, S. Santagata, and M. Barontini A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas PLoS Genetics. 1 1 2005 Jul 72 80
61. G. Eisenhofer, T.T. Huynh, K. Pacak, F.M. Brouwers, M.M. Walther, and W.M. Linehan Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome Endocrine-Related Cancer 11 4 2004 Dec 897 911
62. C.V. Dang, J.W. Kim, P. Gao, and J. Yustein The interplay between MYC and HIF in cancer Nature Reviews. Cancer 8 1 2008 Jan 51 56
63. A. Toschi, E. Lee, N. Gadir, M. Ohh, and D.A. Foster Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2 Journal of Biological Chemistry 283 50 December 12, 2008 34495 34499 2008
64. M.A. Esteban, M.G. Tran, S.K. Harten, P. Hill, M.C. Castellanos, and A. Chandra Regulation of E-cadherin expression by VHL and hypoxia-inducible factor Cancer Research 66 7 2006 Apr 1 3567 3575
65. W.G. Kaelin Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer Nature Reviews. Cancer 8 11 2008 Nov 865 873
66. E.A. Cho, L.T. Patterson, W.T. Brookhiser, S. Mah, C. Kintner, and G.R. Dressler Differential expression and function of cadherin-6 during renal epithelium development Development 125 5 1998 Mar 803 812
67. R.C. Russell, and M. Ohh The role of VHL in the regulation of E-cadherin: a new connection in an old pathway Cell Cycle 6 1 2007 Jan 1 56 59
68. S.K. Harten, D. Shukla, R. Barod, A. Hergovich, M.S. Balda, and K. Matter Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin Molecular Biology of the Cell. 20 3 2009 Feb 1089 1101
69. W.G. Kaelin Jr. ROS: really involved in oxygen sensing Cell Metabolism 1 6 2005 Jun 357 358
70. J.K. Brunelle, E.L. Bell, N.M. Quesada, K. Vercauteren, V. Tiranti, and M. Zeviani Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation Cell Metabolism 1 6 2005 Jun 409 414
71. R.D. Guzy, B. Hoyos, E. Robin, H. Chen, L. Liu, and K.D. Mansfield Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing Cell Metabolism 1 6 2005 Jun 401 408
72. K.D. Mansfield, R.D. Guzy, Y. Pan, R.M. Young, T.P. Cash, and P.T. Schumacker Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation Cell Metabolism 1 6 2005 Jun 393 399
73. K. Block, Y. Gorin, P. Hoover, P. Williams, T. Chelmicki, and R.A. Clark NAD(P)H oxidases regulate HIF-2alpha protein expression The Journal of Biological Chemistry. 282 11 2007 Mar 16 8019 8026
74. J.K. Maranchie, J.R. Vasselli, J. Riss, J.S. Bonifacino, W.M. Linehan, and R.D. Klausner The contribution of VHL substrate binding and HIF1- to the phenotype of VHL loss in renal cell carcinoma Cancer Cell. 1 3 2002 247 255
75. T. Acker, A. Diez-Juan, J. Aragones, M. Tjwa, K. Brusselmans, and L. Moons Genetic evidence for a tumor suppressor role of HIF-2alpha Cancer Cell. 8 2 2005 Aug 131 141
76. C.R. Thoma, I.J. Frew, C.R. Hoerner, M. Montani, H. Moch, and W. Krek pVHL and GSK3beta are components of a primary cilium-maintenance signalling network Nature Cell Biology. 9 5 2007 May 588 595
77. C.R. Thoma, I.J. Frew, and W. Krek The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance Cell Cycle 6 15 2007 Aug 1 1809 1813
78. M. Ohh, R.L. Yauch, K.M. Lonergan, J.M. Whaley, A.O. Stemmer-Rachamimov, and D.N. Louis The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Molecular Cell. 1 7 1998 959 968
79. N.H. Stickle, J. Chung, J.M. Klco, R.P. Hill, W.G. Kaelin Jr., and M. Ohh pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development Molecular and Cellular Biology. 24 8 2004 Apr 3251 3261
80. P.L. Dahia Evolving concepts in pheochromocytoma and paraganglioma Current Opinion in Oncology 18 1 2006 Jan 1 8
81. E.A. Lipscomb, P.D. Sarmiere, and R.S. Freeman SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons The Journal of Biological Chemistry. 276 7 2001 Feb 16 5085 5092
82. S. Lee, E. Nakamura, H. Yang, W. Wei, M.S. Linggi, and M.P. Sajan Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer Cancer Cell. 8 2 2005 Aug 155 167
83. Y. Qin, K. Buddavarapu, and P.L. Dahia Pheochromocytomas: from Genetic Diversity to New Paradigms Hormone and Metabolic Research 41 9 2009 Sep 664 671
84. T. Bishop, D. Gallagher, A. Pascual, C.A. Lygate, J.P. de Bono, and L.G. Nicholls Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice Molecular and Cellular Biology. 28 10 2008 May 3386 3400
85. S. Schlisio, R.S. Kenchappa, L.C. Vredeveld, R.E. George, R. Stewart, and H. Greulich The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor Genes & Development. 22 7 2008 Apr 1 884 893
86. I.T. Yeh, R.E. Lenci, Y. Qin, K. Buddavarapu, A.H. Ligon, and E. Leteurtre A germline mutation of the KIF1Bbeta gene on 1p36 in a family with neural and nonneural tumors Human Genetics 124 3 2008 Oct 279 285
87. A.P. Young, S. Schlisio, Y.A. Minamishima, Q. Zhang, L. Li, and C. Grisanzio VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 Nature Cell Biology 10 3 2008 Mar 361 369
88. C.R. Thoma, A. Toso, K.L. Gutbrodt, S.P. Reggi, I.J. Frew, and P. Schraml VHL loss causes spindle misorientation and chromosome instability Nature Cell Biology. 11 8 2009 Aug 994 1001
89. W.G. Kaelin Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein Cancer 115 10 Suppl 2009 May 15 2262 2272
90. I.R. Konings, J. Verweij, E.A. Wiemer, and S. Sleijfer The applicability of mTOR inhibition in solid tumors Current Cancer Drug Targets 9 3 2009 May 439 450